The phase 3, open-label, clinical trial for ATTRv patients with PN, NEURO-TTRansform trial, compared eplontersen with the placebo cohort of the NEURO-TTR trial, showing a significantly lowered serum TTR concentration, less neuropathy impairment and better QoL. This evidence concerns the gene TTR and neuropathy.